This is an aggregated industry headline. Read the full story at BioPharma Dive →
Kardigan extends biotech's streak of big IPOs with $400M haul
Including the heart drug developer's offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds - the most in a single year since 2021, according to BioPharma Dive data.
By BioPharma Dive
· Jun 18, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treat…
The WeekFierceBiotech ↗
F2G and Shionogi have released phase 3 data for the oral antifungal drug olorofim, demonstrating its non-infer…
The WeekBriefing
Regulators appear receptive to Moderna's flu vaccine, UniQure prepares a Huntington's filing, and Lilly announ…